• |
  • |
  • |
  • |
Donate

Product

Genetic subgroup learnings from the MMPOWER-3 trial: elamipretide improved six-minute walk in patients with mtDNA replisome mutations.

Center:
Fiscal Year:
2021
Contact Information:
Product Description:
Keyword(s):
Product/Publication Type(s):
Other
Target Audience:
Professionals, Students
Alternative Format:
To Obtain Copies (URL or Email):
COVID-19 Related Data:
N/A